Treatment Response and 5-Year Survival Outcome in Breast Cancer Patients After the Use of MammaPrint and BluePrint to Guide Preoperative Systemic Therapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
European Journal of Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Treatment response and 5-year distant metastasis-free survival outcome in breast cancer patients after the use of MammaPrint and BluePrint to guide preoperative systemic treatment decisions
Eur. J. Cancer 2022 May 01;167(xx)92-102, E Göker, MP Hendriks, M van Tilburg, A Barcaru, L Mittempergher, A van Egmond, M Kleijn, D GeneraliFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.